Rodent Carcinogenicity: Mechanistic Dissection

Two-year carcinogenicity studies are required by the FDA for all new drugs expected to be used chronically. For GLP-1 receptor agonists, these studies have consistently produced thyroid C-cell pathology in rats, and understanding the mechanism is key to assessing human relevance.

The GLP-1R/Calcitonin Axis in Rodents

Rat thyroid C-cells express GLP-1 receptors at high density. Chronic GLP-1 receptor stimulation activates adenylyl cyclase, increasing intracellular cAMP, which drives both calcitonin gene transcription and C-cell proliferation. This mechanism has been confirmed through multiple approaches: in vitro studies using isolated rat C-cell lines, ex vivo thyroid slice cultures, and in vivo pharmacology studies.

The proliferative response follows a predictable progression: C-cell hyperplasia (increased cell number without structural disorganization) progresses to C-cell adenoma (benign tumor), which in some animals progresses to C-cell carcinoma (MTC). This sequence is dose-dependent and time-dependent, consistent with a classical tumor promotion mechanism rather than direct genotoxicity.

Dose-Exposure Relationships

For semaglutide, C-cell tumors in rats were observed at the lowest dose tested (0.01 mg/kg/day), which produces plasma exposures approximately 2-fold the exposure at the maximum recommended human dose (MRHD). At the highest dose (0.25 mg/kg/day), exposure was approximately 10-fold MRHD. The incidence of malignant C-cell carcinomas at the highest dose was approximately 10% in males and 8% in females, compared to 0% in control animals.

An important consideration is that two-year rat studies represent approximately one-third of the rat lifespan, equivalent to roughly 25 to 30 human years. This extended relative exposure period may contribute to the tumor findings.

Mouse Carcinogenicity Data

In contrast to rats, mouse carcinogenicity studies with semaglutide showed C-cell hyperplasia but markedly fewer C-cell tumors. This species difference has been investigated and may relate to lower GLP-1 receptor density on mouse C-cells compared to rats. Mice occupy an intermediate position between rats and humans in terms of C-cell GLP-1 receptor expression.

Human C-Cell GLP-1 Receptor Biology

The central question for human risk assessment is whether human thyroid C-cells express functional GLP-1 receptors. The answer, based on over a decade of research, is nuanced but largely reassuring.

Receptor Expression Studies

The first study to examine human C-cell GLP-1R expression (Korner et al., 2007) used in vitro receptor autoradiography and reported GLP-1 receptor expression in human MTC tumors and some normal C-cells. However, this technique cannot distinguish between specific and nonspecific binding with certainty.

A subsequent study by Waser et al. (2015) using validated monoclonal antibodies (MAb 3F52) found GLP-1R protein expression in approximately 28% of human MTC samples but no detectable expression in normal human thyroid tissue. Importantly, even in MTC tumors that expressed the receptor, the density was substantially lower than in rat C-cells.

Transcriptomic approaches have provided additional clarity. RNA sequencing of human thyroid tissue reveals minimal GLP-1R transcript in normal C-cells. Single-cell RNA sequencing from the Human Protein Atlas and independent studies confirms that GLP-1R mRNA is expressed at near-background levels in human parafollicular (C-cells), in stark contrast to the robust expression seen in rat C-cells.

Functional Studies

Functional assays have tested whether GLP-1 receptor agonists stimulate calcitonin release from human thyroid tissue:

• Ex vivo human thyroid tissue studies: GLP-1 receptor agonists failed to stimulate calcitonin release from normal human thyroid tissue, while positive controls (calcium, pentagastrin) produced expected calcitonin responses.
• Human MTC cell line studies: The TT cell line (human MTC) shows variable GLP-1R expression. Some studies report modest calcitonin stimulation with GLP-1 agonists, while others do not. The relevance of MTC cell lines to normal C-cell biology is limited
• Clinical pharmacology studies: Single-dose and multiple-dose pharmacology studies of GLP-1 receptor agonists in healthy volunteers show no increase in serum calcitonin levels

Collectively, the functional evidence strongly suggests that human C-cells lack sufficient GLP-1 receptor expression to mount a proliferative response to chronic GLP-1 receptor agonist exposure.

Calcitonin Monitoring Data from Clinical Trials

Serum calcitonin is the most sensitive clinical biomarker for C-cell activation. If GLP-1 receptor agonists stimulated human C-cell proliferation, chronic elevation of calcitonin would be expected. The clinical trial data on this point is extensive and reassuring.

Semaglutide Trial Calcitonin Data

Across the SUSTAIN program (injectable semaglutide for type 2 diabetes), serial calcitonin measurements were performed. No clinically meaningful differences in calcitonin levels were observed between semaglutide and placebo groups at any timepoint through 2 years. The proportion of patients with calcitonin values exceeding the upper limit of normal was comparable between groups.

The STEP program (semaglutide 2.4 mg for obesity) similarly showed no calcitonin elevation signal. The SELECT trial, with the longest follow-up (mean 3.3 years), also reported no meaningful calcitonin differences between semaglutide and placebo groups.

Class-Wide Calcitonin Evidence

Calcitonin data from liraglutide trials (LEADER, SCALE program), dulaglutide trials (REWIND, AWARD program), and exenatide trials (EXSCEL) are all consistent: no chronic calcitonin elevation with GLP-1 receptor agonist therapy in humans. A pooled analysis of calcitonin data across more than 12,000 patients and up to 5 years of follow-up found no treatment-related calcitonin increase.

This body of calcitonin evidence is the single strongest argument against human C-cell stimulation by GLP-1 receptor agonists. If the rodent mechanism were operative in humans, chronic calcitonin elevation would be expected and has never been observed.

Epidemiological Evidence: Critical Analysis

The French Database Study in Detail

The most widely discussed observational study was published by Bezin et al. in 2023, using the French national healthcare database (SNDS). This study followed 2.5 million patients with type 2 diabetes from 2006 to 2017 and compared thyroid cancer incidence between GLP-1 RA users and non-users.

Key findings included a hazard ratio of 1.58 (95% CI, 1.27 to 1.95) for all thyroid cancers with 1 to 3 years of GLP-1 RA use, attenuating to non-significant levels with longer use. Several critical methodological issues limit interpretation:

• Histological subtype not available: The study could not distinguish MTC from papillary thyroid cancer, the most common subtype. If the signal is driven by papillary cancer (which is not mechanistically linked to GLP-1R), the rodent concern is irrelevant
• Detection bias: GLP-1 RA users have more frequent medical visits and imaging, increasing the likelihood of incidental thyroid nodule detection (surveillance bias)
• Confounding by indication: Obesity and diabetes themselves may increase thyroid cancer risk
• Temporal pattern: The increased risk in years 1-3 with attenuation afterward is inconsistent with a progressive carcinogenic mechanism and more consistent with detection bias

Nordic Registry Data

Studies from Denmark, Sweden, and Norway using national prescription and cancer registries have generally not found an association between incretin therapy and thyroid cancer. A Danish cohort study with over 12 years of follow-up found no increased thyroid cancer risk with GLP-1 RA or DPP-4 inhibitor use (HR 0.98; 95% CI, 0.65 to 1.48).

US Claims Database Studies

Analyses of US commercial insurance databases have produced mixed results, with some showing modest associations for thyroid cancer overall and others finding no signal. None have been able to specifically examine MTC due to its rarity and coding limitations.

Regulatory Perspectives

Regulatory agencies have approached the thyroid safety question with appropriate caution while acknowledging the evolving evidence.

FDA Position

The FDA has maintained the boxed warning for all GLP-1 receptor agonists since exenatide's approval. The agency has stated that the warning will remain until definitive human evidence either confirms or excludes a clinically meaningful risk. The FDA has also noted that the human calcitonin data is reassuring.

EMA Position

The European Medicines Agency (EMA) does not require a boxed-warning equivalent for GLP-1 receptor agonists regarding thyroid cancer. The EMA product information includes precautionary language but frames the risk as a class effect observed in rodents with uncertain human relevance. This regulatory divergence reflects different risk communication approaches rather than different interpretations of the data.

Expert Panel Recommendations

A 2023 expert consensus statement from endocrinologists, oncologists, and pharmacologists concluded that "the available evidence does not support a causal link between GLP-1 receptor agonist use and thyroid cancer in humans" while recommending continued surveillance. The panel explicitly stated that the boxed warning should not deter clinicians from prescribing GLP-1 RAs when clinically indicated.

Tirzepatide and Thyroid Safety

Tirzepatide, the dual GIP/GLP-1 receptor agonist, carries the same boxed warning for thyroid C-cell tumors. Rat carcinogenicity studies with tirzepatide also showed C-cell tumors, consistent with the GLP-1 receptor agonist class effect.

An interesting research question is whether the additional GIP receptor component of tirzepatide modifies the thyroid safety profile. GIP receptors are not known to be expressed on thyroid C-cells, so the GIP component likely does not add to the thyroid concern. Human calcitonin data from the SURPASS and SURMOUNT trial programs are consistent with other GLP-1 RAs, showing no chronic calcitonin elevation.

Research Priorities and Unanswered Questions

• Definitive characterization of GLP-1R protein expression in normal human C-cells using the latest validated antibodies and spatial transcriptomics
• Long-term (10+ year) epidemiological surveillance specifically examining MTC incidence in GLP-1 RA users
• Population-based MTC incidence trend analysis using SEER data to detect any temporal shift coinciding with GLP-1 RA market uptake
• Genetic studies examining whether RET or other MTC susceptibility gene variants modify any potential GLP-1 RA thyroid risk
• Calcitonin procalcitonin monitoring in very long-term (5+ year) GLP-1 RA users
• Thyroid tissue sampling from GLP-1 RA exposed patients undergoing thyroidectomy for unrelated reasons

These research priorities reflect the scientific community's commitment to resolving the question definitively while the accumulating evidence continues to be reassuring.

Frequently Asked Questions

Why do rats get thyroid cancer from GLP-1 medications but humans apparently do not?

The primary reason is a species difference in GLP-1 receptor expression on thyroid C-cells. Rat C-cells have high GLP-1 receptor density and respond to chronic stimulation with proliferation and tumor formation. Human C-cells have minimal GLP-1 receptor expression and do not show calcitonin elevation or proliferative responses to GLP-1 receptor agonists. Additionally, rats have a higher proportion of C-cells in their thyroid glands.

Could thyroid cancer risk emerge with longer human exposure?

This cannot be entirely excluded, which is why ongoing surveillance is important. However, several factors argue against a late-emerging risk: (1) calcitonin levels show no upward trend even with years of treatment, (2) clinical trial data through 3 to 5 years show no signal, (3) the biological basis for human C-cell stimulation is weak. Liraglutide has been on the market since 2010, providing over 15 years of real-world exposure data without a confirmed MTC signal.

Should I check my thyroid before starting semaglutide?

Routine thyroid ultrasound or calcitonin testing before starting semaglutide is not recommended by clinical guidelines. A thorough personal and family medical history focusing on MTC and MEN2 syndrome is the appropriate screening measure. If you have a thyroid nodule or a family history of thyroid cancer, discuss this with your doctor before starting GLP-1 therapy. pre-treatment screening

Does the thyroid risk differ between injectable and oral semaglutide?

Both formulations carry the same boxed warning. The rodent carcinogenicity data apply to the semaglutide molecule regardless of the route of administration. Oral semaglutide (Rybelsus) achieves lower systemic exposure than injectable semaglutide at approved doses, but this does not meaningfully change the risk assessment, as the human evidence does not confirm a risk with either formulation.

If I have thyroid nodules, can I still take semaglutide?

Thyroid nodules are extremely common, present in up to 50% of adults on ultrasound. Most nodules are benign and are not a contraindication to semaglutide. However, if a nodule has suspicious features or has not been evaluated, it should be assessed before starting therapy. Any nodule with features concerning for MTC (elevated calcitonin, suspicious cytology) would warrant full workup before considering GLP-1 therapy.

Are there any GLP-1 medications that do not have the thyroid warning?

No. All currently approved GLP-1 receptor agonists carry the C-cell tumor boxed warning because all produce tumors in rat carcinogenicity studies. This is considered a class effect related to the GLP-1 receptor agonist mechanism of action. Tirzepatide also carries the warning due to its GLP-1 receptor agonist component.

How does the thyroid cancer risk compare to the benefits of semaglutide?

The risk-benefit analysis strongly favors treatment. The theoretical thyroid cancer risk is unconfirmed in humans and, even if real, would affect perhaps 1 to 2 additional people per million per year. In contrast, the proven benefits include 14% MACE reduction, 12% mortality reduction, significant weight loss, kidney protection, and liver health improvement. For patients without MTC risk factors, the benefits overwhelmingly outweigh the theoretical thyroid concern.

Conclusion

The thyroid C-cell tumor question represents one of the most thoroughly investigated safety concerns in modern pharmacology. The rodent data are clear and reproducible, but the weight of evidence from species-specific receptor biology, human calcitonin monitoring, clinical trial thyroid cancer events, and epidemiological surveillance consistently suggests that GLP-1 receptor agonists do not stimulate human C-cell proliferation or cause thyroid cancer in humans. The boxed warning serves an important precautionary function and ensures informed consent, but it should not be a barrier to prescribing these beneficial medications when clinically appropriate.

At Form Blends, we stay informed on the latest thyroid safety research and discuss these findings transparently with our patients. Our physician-supervised approach ensures that every patient receives appropriate screening and monitoring. get started Starting at $199/mo